Business Wire

MA-VERACODE

23.5.2023 17:27:28 CEST | Business Wire | Press release

Share
Veracode Named a Leader in the Magic Quadrant™ Application Security Testing For 10th Consecutive Time

Veracode, a leading provider of intelligent software security solutions, has been positioned as a 10-time Leader in the 2023 Gartner Inc. Magic Quadrant for Application Security Testing—an in-depth evaluation of the market’s competitors. The company has been recognized as a Leader in the report every single time since it was first published.

With independent feedback and ratings from customer reviews culminating in a 97 percent “willingness to recommend” (based on 61 reviews, as of 31 July 2022), Veracode was also positioned as a Gartner Peer Insights™ Customers’ Choice for Application Security Testing.

Sam King, Chief Executive Officer at Veracode, said, “For more than 17 years, we have had an unrelenting commitment to making secure software a competitive advantage for our customers. Our continued position as a Leader in the Gartner Magic Quadrant, combined with our recognition as a Customers’ Choice, we feel demonstrates the trust placed in us every day by developers, security teams, and business leaders worldwide. We are proud to say that Veracode was one of the pioneers of application security and now we are propelling the category into the future: intelligent software security.”

The Head of Application Security at a banking company reviewing Veracode in Gartner Peer Insights™ said, “Of all the companies that carry out POCs (Proof of Concepts)...only Veracode proves to be a solid and senior company or enough to put in our financial institution." A security analyst at another firm commented, “In order for a product to be successful, it needs to do two things right, ‘product performance’ and ‘support’. Veracode gives you the best of both worlds, a great product with great support.”

Protecting the Software Supply Chain

Veracode offers EU and UK Support through its dedicated European Region, an EU instance that allows European organizations to address data residency concerns. The company has also achieved the US Federal Risk and Authorization Management Program (FedRAMP), which makes multiple tools available to US federal agencies that want to find and fix software supply chain vulnerabilities in accordance with compliance mandates. Veracode is the only software composition analysis vendor listed in the FedRAMP marketplace.

King said, “Increased reliance on third-party code, along with emerging regulations for software security and data compliance, are some of our customers’ greatest challenges. To alleviate the pressure on organizations, our proprietary database tracks open-source risk and our platform provides continuous scanning through multiple tools, including container security, infrastructure-as-code (IaC) scanning, and Software Bill of Materials (SBOM) capabilities.”

Veracode’s recent addition of Peer Benchmarking—a new self-service capability that allows organizations to measure their flaw and remediation performance against industry peers—also enables security leaders to assess the impact of their investments and demonstrate value to the business.

Strength of Vision: Delivering Capabilities Against Customer Needs

In the past year, Veracode has also made two significant acquisitions, to which the company credits its position in the report. Firstly, the acquisition of the Germany-based Crashtest Security tool enhanced Veracode’s existing dynamic analysis and penetration testing capabilities for web apps and application programming interfaces (APIs), as well as broadening customer access globally. More recently, the acquisition of auto-remediation technology from Jaroona, a 2021 Gartner® Cool Vendor™ for DevSecOps, enabled the launch of Veracode Fix. The new AI-powered product automatically suggests remediations for security flaws found in code and open-source dependencies.

Brian Roche, Chief Product Officer at Veracode, said, “One of the biggest pain points our customers express is mitigating intensifying threat against an expanding attack surface, while accelerating development velocity and minimizing costs. We’ve invested heavily in our platform over the past year to develop automated solutions that remove friction for developers and provide security teams with a comprehensive view of risk. The launch of Veracode Fix addresses the need to broaden our focus from application security testing to intelligent software security.”

To download a complimentary copy of the full 2023 Gartner Magic Quadrant Report, visit the Veracode website.

To learn more about intelligent software security from Veracode, please visit: https://www.veracode.com/products

1Gartner, Magic Quadrant for Application Security Testing, Mark Horvath, Dale Gardner, Manjunath Bhat, Ravisha Chugh, Angela Zhao, 17 May 2023.

2Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, September 30, 2022.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant, Cool Vendors and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

About Veracode

Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Prompted by powerful AI trained by trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.

Copyright © 2023 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005707/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye